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Abstract 
Recently, our research team proposed a new histological staging and grading system for 
primary biliary cirrhosis (PBC) that takes into account necroinflammatory activity and 
histological heterogeneity. The present study aimed to confirm the usefulness of the new 
evaluating system. A total of 152 liver biopsy specimens and clinical data (including 
outcomes in patients with PBC before treatment with ursodeoxycholic acid) were analyzed 
with respect to the new system. Staging was evaluated on the basis of 3 histological 
components (fibrosis, bile duct loss, and deposition of orcein-positive granules), and grading 
was assessed on the basis of chronic cholangitis activity (CA) and hepatitis activity (HA). 
Concurrently, the classical systems, i.e., the Scheuer and Ludwig staging systems, were also 
assessed and compared with our new system. PBC cases showed different distributions in 
each stage of the 3 systems. The new staging and grading system reflected liver dysfunctions 
before specific treatment. This was on a par with the results obtained using the classical 
systems. Development of cirrhosis-related conditions correlated well with the new staging 
system compared with the 2 classical staging systems, and in particular, the amount of 
deposition of orcein-positive granules could reflect development of cirrhosis-related 
conditions (scores 0– 1 vs. scores 2–3 groups p < 0.0001). In conclusion, the new PBC 
staging system was demonstrated to reflect clinicolaboratory features, and its progression was 
associated with the development of cirrhosis-related conditions.  
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1. Introduction 
 Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown cause. 
Histologically, interlobular bile ducts are selectively affected, presenting chronic 
non-suppurative destructive cholangitis (CNSDC). After cholangiopathy, the affected bile 
ducts finally disappear, causing cholestatic liver failure and cirrhosis (1, 2).  
 Several histological staging systems for PBC have been proposed since the 1960s, 
including those by Scheuer (3), Rubin et al (4), and Ludwig et al (5). In the staging systems 
devised by Scheuer and Ludwig et al, PBC is classified into 4 stages according to a single 
histological feature (e.g., CNSDC and fibrosis), similar to the system used for chronic 
hepatitis. These classical systems have been used widely, but the staging process is subjective. 
Moreover, the histological features of PBC are heterogeneously distributed in the entire liver; 
therefore, sampling errors are often encountered in the same liver biopsy specimens. In the 
staging system devised by Rubin et al (4), the cirrhotic stage is described clearly but the 
distinctions among the 3 pre-cirrhotic stages are not. 
 Recently, we proposed a new grading and staging system for PBC that takes into 
account the histological findings of cholangitis and hepatitis activities for grading as well as 
those of fibrosis, bile duct loss, and chronic cholestasis for staging (6). Furthermore, we have 
proposed a revised and more practical version of this new grading and staging system for liver 
biopsy (7-9). In the present study, we attempted to evaluate our new staging and grading 
system by examining relationships with clinicolaboratory features, including outcomes in 152 
patients with PBC. 
Y. Kakuda et al. 6 
 
 
2. Materials and Methods 
2.1. Patient selection and tissue preparations 
A total of 152 patients were enrolled in this study. They were histologically diagnosed with 
PBC on the basis of liver biopsies (144 needle biopsies and 8 wedge biopsies). All patients 
received no specific treatments such as ursodeoxycholic acid (UDCA) at the time of biopsy 
and were serologically negative for hepatitis B surface antigen or hepatitis C antibody. These 
152 cases were selected consecutively from the files of Kanazawa University Hospital and 
Department of Human Pathology, Kanazawa Medical Center, Kanazawa Red Cross Hospital 
and Fukui Prefectural Hospital from 1989 to 2011. The 152 cases included 42 cases that had 
been used in our previous study (6). Biochemical data [levels of alkaline phosphatase (Alp), 
gamma-glutamyl transpeptidase (γ-GTP), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and total bilirubin)] and data on clinical features [gastroesophageal 
varices assessed by gastrointestinal endoscopy and ascites examined by ultrasonography or 
computed tomography] were collected for 6 months before biopsy. All liver biopsy specimens 
were processed routinely, and thin sections were stained with hematoxylin and eosin (H&E), 
reticulin, Azan–Mallory, and orcein stains. All these liver specimens contained at least 7 
portal tracts, including 5 complete portal tracts, i.e., a portal tract having a portal vain and 
hepatic arterial branch with or without a bile duct, with an elastic tissue framework confirmed 
by H&E and orcein staining. 
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2.2. A new histological staging and grading system for PBC 
Representative histological findings of PBC as defined by our new histological staging and 
grading system are shown in Fig. 1.  
2.2.1. Staging: Three lesions (fibrosis, bile duct loss, and deposition of orcein-positive 
granules) were evaluated for staging. Orcein-positive granules are copper-binding proteins 
that reflect chronic cholestasis. These 3 items were scored as shown in Table 1. After each of 
these items was scored, a total was obtained: a total score of 0 was stage 1 (no or minimum 
progression), 1–3 was stage 2 (mild progression), 4–6 was stage 3 (moderate progression), 
and 7–9 was stage 4 (advanced progression). 
2.2.2. Grading: Chronic cholangitis, including CNSDC, and hepatitis-like changes are 
representative necroinflammatory lesions of PBC, and they were assessed as shown below 
and in Table 2. 
Cholangitis activity (CA): CNSDC was characterized by marked damage to the epithelium of 
the bile ducts. This was manifested as disarrayed epithelia with swollen or shrunken 
eosinophils, surrounded entirely by marked duct-oriented lymphoplasmacytic infiltration 
and/or periductal epithelioid granulomas (Fig. 1A and 1B). In contrast, “evident chronic 
cholangitis” was defined as non-specific chronic cholangitis surrounded entirely by 
mild-to-moderate duct-oriented lymphoplasmacytes (Fig. 1C), which is similar to the type of 
cholangitis encountered occasionally in chronic viral hepatitis (9). Interlobular bile ducts, 
which were surrounded by a small number of lymphoplasmacytes or were adjacent to 
infiltration of lymphoid cells in the portal tract, were not regarded as evident chronic 
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cholangitis. In grade 3, at least one damaged bile duct showing CNSDC or a florid duct lesion 
(3, 4) was found. 
Hepatitis activity (HA): “Interface hepatitis” is defined as lymphocytic interface activity 
showing damaged hepatocytes with lymphocyte infiltration at the interface of portal tracts or 
fibrous septa (2, 7). Degree of lobular hepatitis is also taken into account for HA grading.  
 
2.3. Histological evaluation 
Biopsy slides were evaluated by 3 pathologists (Y.K, K.H, and Y.N) using the new staging and 
grading system and 2 widely used classical staging systems: the Scheuer system (3) (i.e., 
stage 1: florid duct lesions or CNSDC; stage 2: proliferation of bile ductules; stage 3: fibrosis 
or scarring; and stage 4: cirrhosis) and the Ludwig system (5) (i.e., stage 1: portal hepatitis; 
stage 2: periportal hepatitis; stage 3: bridging fibrosis or necrosis; and stage 4: cirrhosis). 
Grading and staging were evaluated by consensus using a multiheaded microscope and a 
semiquantitative approach. The HA grade was discrepant in approximately 1/5 of cases 
among the 3 pathologists, but after discussion, a consensus regarding the appropriate grade 
was reached. 
 
2.4. Definitions of endpoint 
The terminal morphological feature of PBC is cirrhosis (10). The number of patients for 
whom additional follow-up liver biopsies were performed after diagnosis was limited (n = 21). 
Hence, we set the endpoint as the occurrence of cirrhosis-related conditions defined by at least 
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one of the following events: histologically proven cirrhosis or cirrhosis-related complications 
and/or symptoms, i.e., ascites, ruptured and/or endoscopically treated gastroesophageal 
varices, hepatic encephalopathy, hyperbilirubinemia (≥2.0 mg/dL), or hepatocellular 
carcinoma. 
  
2.5. Statistical analyses 
Data are expressed as mean ± standard deviation. Correlations and comparisons of 
biochemical data of each grade, score, or stage were examined using Spearman's correlation 
coefficient by rank test. Rates of development of cirrhosis-related conditions were estimated 
using the Kaplan–Meier method and log rank test. All analyses were 2-sided, and p < 0.05 
was considered significant. All statistical analyses were performed using JMP software 8.0 
(SAS Institute Inc., Cary, NC, USA).  
 
3. Results 
3.1. Distribution of histological grades, scores, and stages 
The main clinical profile and laboratory data of 152 patients with PBC are shown in Table 3. 
The distribution of grades of CA and HA and scores of the 3 lesions for staging (fibrosis, bile 
duct loss, and deposition of orcein-positive granules) are shown in Fig. 2A–E. As for 
necroinflammatory activity, CA3 was the most frequent and CA0, CA1, and CA2 were 
relatively infrequent. In contrast, HA1 was the most frequent, followed by HA0, HA2, and 
HA3, indicating that the hepatic form of PBCsuch as HA2 and HA3 (2, 11, 12) was the least 
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frequent. With regard to the scores of the 3 lesions, scores 0 and 1 were predominant in each 
lesion.  
    The distribution of cases according to the new system and classical two staging systems 
are shown in Fig. 2F–H. Two main findings were noted. First, 95 and 2 of 123 cases of 
Scheuer stage 1 as well as 20 of 36 cases of Ludwig stage 1 were reclassified as stages 2 and 
3 of the new staging system. This was because at least one of the histological lesions (i.e., 
fibrosis, bile duct loss, or deposition of orcein-positive granules) was present in these cases of 
Scheuer/Ludwig stage 1. Second, 5 of 9 cases classified as stage 4 of the new staging system 
were reclassified as Scheuer/Ludwig stage 3. This was because these cases showed high 
scores of bile duct loss and/or deposition of orcein-positive granules but not cirrhosis. 
 
3.2. Relationship between blood biochemistry and the new system and classical staging 
systems 
Herein, we excluded the 42 patients used as cases for the previous study in which this new 
grading and staging system had been proposed (6). Therefore, the remaining 110 cases were 
evaluated. Using Spearman's correlation coefficient by rank test, it was found that Alp, γ-GTP, 
AST, and ALT levels were positively correlated with CA and HA grades; the new staging 
system and its components (scores of fibrosis, bile duct loss, and deposition of orcein-positive 
granules); and the 2 classical staging systems (Table 4). Deposition of orcein-positive 
granules, the new staging system, and the Scheuer staging system also correlated with the 
total bilirubin level, but the Ludwig staging system did not. Instead, the Ludwig staging 
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system correlated with IgM and IgG levels. HA grade also correlated with the IgG level. 
Interestingly, AMA and antinuclear antibody titers did not show significant correlation with 
any staging systems, HA and CA grades, or other histological lesions for staging.  
 
3.3. Histological lesions, staging systems, and patient outcome 
All patients were followed up for a mean period of 5 years (range, 0–24.8 years). A total of 
136 patients were treated with UDCA after liver biopsies (Table 3), whereas 9 patients were 
followed up (range, 0.5–5 years) without UDCA treatment because of early stage of stable 
disease. The remaining 7 patients changed the hospital immediately after liver biopsy and 
could not be followed up. A total of 23 patients presented with one or several cirrhosis-related 
conditions (Table 5), and such condition(s) were already observed in 9 patients at the time of 
liver biopsy and developed during follow-up in the remaining 14 patients. Therefore, these 9 
cases were excluded from the subsequent prognostic studies. 
    The development of cirrhosis-related conditions at 10 years of follow-up in the 3 systems 
(Fig. 3) was found in 0%, 12.6%, 40.6%, and 100% of stage 1, 2, 3, and 4 cases of the new 
system; 7.5%, 100% (at 5 years), and 40.3% of stage 1, 2, and 3 cases of the Scheuer system; 
and 17.6%, 4.6%, and 47.4% of stage 1, 2, and 3 cases of the Ludwig system. Using the log 
rank test, all 3 systems showed significance with the development of these complications 
and/or symptoms (p < 0.01). Interestingly, the rate of development increased according to the 
stage progression of the new system, and significant difference was observed between stages 
2 and 3 (p < 0.01). Moreover, stage 1 patients of the new staging system did not show such 
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findings during follow-up. However, no such tendencies were observed in the 2 classical 
staging systems. 
   Five of 9 patients of stage 4 in the new system were not cirrhotic (as assessed by 
histology) at the time of liver biopsy. Two of these 5 cases already presented with any 
cirrhosis-related condition at the time of liver biopsy, and the other 2 cases developed such 
conditions during follow-up. The remaining patient was lost to follow-up.  
   The development of cirrhosis-related conditions and CA and HA grades did not show a 
significant correlation (data not shown). With respect to the histological findings that defined 
the new staging system, a significant correlation was observed between these findings and 
fibrosis and deposition of orcein-positive granules, but such analyses were not possible 
because few cases exhibited score 2 or 3 of bile duct loss (Fig. 4A and B). In particular, the 
rate of development of cirrhosis-related conditions in patients with scores 2–3 of deposition of 
orcein-positive granules was significantly higher than that in patients with scores 0–1 (p < 
0.0001) (Fig. 4C). 
4. Discussion 
   Recently, we proposed a new histological evaluation system for liver biopsies of PBC to 
avoid sampling errors and to evaluate necroinflammatory activities. In the present study, we 
applied this new system to the liver biopsies of 152 patients with PBC. We found different 
distributions of cases among the 3 systems. In particular, a considerable number of stage 1 
cases of the Scheuer/Ludwig systems were reclassified as stage 2 or 3 in the new system 
because of bile duct loss and/or deposition of orcein-positive granules in the absence of 
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ductular proliferation or interface hepatitis. Histological heterogeneity in the liver may be a 
reason for such differences. In addition, several stage 3 cases of the Scheuer/Ludwig systems 
were reclassified as stage 4 because of extensive bile duct loss or deposition of orcein-positive 
granules despite the absence of cirrhotic changes. This finding may reflect the more accurate 
evaluation of pathological progression by our new system (see below). 
   We then analyzed PBC patients before UDCA therapy with respect to clinicolaboratory 
and histological findings using the 3 staging systems. In this evaluation, the patients who had 
been used as cases for our previous study (6), in which the new grading and staging system 
had been proposed, were excluded. The new system and the 2 classical systems were found to 
correlate well with Alp, γ-GTP, AST, and ALT levels. This system and the Scheuer system 
also correlated with the total bilirubin level, whereas the Ludwig staging system did not. 
Instead, the Ludwig staging system correlated with IgG and IgM levels. CA and HA grades 
also correlated with Alp, γ-GTP, AST, and ALT levels, and interestingly, HA grade correlated 
with the IgG level, similar to the Ludwig staging system. Taken together, this new staging 
system combined with HA grade seems to reflect liver dysfunction such as cholestasis and the 
necroinflammatory activities of PBC. However, AMA titer and CA degree, which are both 
characteristic of PBC, were not associated with each other, and the former was not associated 
with any of pathological markers examined. This finding supported the notion that AMA was 
not directly associated with PBC pathogenesis (13).  
   Then, we evaluated the relationship between this system and prognosis using a 
retrospective cohort study. With respect to the development of cirrhosis-related conditions, 
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each of these 3 systems, as a whole, showed significance. Interestingly, the development rates 
increased according to the stage progression of the new system, and significant differences 
were observed between stages 2 and 3. However, no such tendencies were observed in the 
classical staging systems. Taken together, this new system was better for predicting outcome 
(particularly, the development of cirrhosis-related conditions) with respect to prognosis than 
the other 2 classical staging systems.  
   With regard to the grading of PBC, such as CA and HA, and the 3 stage-defining findings, 
the development of cirrhosis-related findings increased along with fibrosis and deposition of 
orcein-positive granules. Fibrosis, interface hepatitis, and ductopenia/bile duct loss have been 
reported to be predictors of PBC progression (14-18). However, the present study results 
indicated that fibrosis and deposition of orcein-positive granules should be regarded as such 
predictor, possibly because of the elimination of cases with advanced-stage PBC at the 
beginning of follow-up in this study. Non-responders for UDCA have been reported to have a 
poorer prognosis than responders (15-17, 19, 20). Further studies investigating the 
relationship of this new system as well as the clinical and biochemical response to UDCA 
therapy using more patients with PBC seem essential to solve this issue.  
   Roll et al (18) also reported cholestasis to be an adverse prognostic factor of PBC. 
Deposition of orcein-positive granules representing copper-binding protein is a very sensitive 
finding reflecting chronic cholestasis (21). The present study demonstrated that the amount of 
deposition of orcein-positive granules was associated with the development of 
cirrhosis-related conditions. The amount of deposition of orcein-positive granules correlated 
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well with blood biochemical data (Table 4). The score of deposition of orcein-positive 
granules is necessary to precisely evaluate PBC progression.   
   In conclusion, we assessed a new staging and grading system for PBC using 152 cases. 
Some of the cases belonging to stage 1 of the Scheuer/Ludwig system and those to stage 3 of 
the Scheuer/Ludwig system were reclassified as stage 2 or 3 and stage 4 in the new staging, 
respectively, raising the possibility that an accurate evaluation of pathological progression 
could be performed using the new system. The new system reflected liver dysfunctions before 
UDCA treatment as well as the 2 classical systems. The development of cirrhosis-related 
conditions increased according to the stage progression of the new system on a step-wise 
basis. Interestingly, deposition of orcein-positive granules was a useful predictive factor for 
the development of cirrhosis-related conditions and was eventually a useful prognostic factor 
for patients with PBC. Studies with larger cohorts involving different institutions seem to be 
necessary to more accurately validate this new histological grading and staging system. 
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Figure legends 
Fig. 1 Histological findings defining the staging and grading of PBC. (A) Chronic 
non-suppurative destructive cholangitis indicates CA3 (arrowhead) (H&E staining, 
400× magnification). (B) CA3 includes granulomatous cholangitis (arrowhead) (H&E 
staining, 400× magnification). (C) Chronic cholangitis (arrowhead). Black arrow 
denotes interface hepatitis affecting approximately 10 hepatocytes (H&E staining, 
400× magnification). (D) Regenerative nodule (*) with interface hepatitis affecting 
approximately 20 hepatocytes in an HA3 case (H&E staining, 400× magnification). 
(E) No interlobular bile ducts are found in this portal tract (bile duct loss) A, hepatic 
artery, P, portal vein (H&E staining, 400× magnification). (F) and (G) Orcein-positive 
granules are deposited in zone 1 hepatocytes around 1 portal tract. (F) A couple of 
zone 1 hepatocytes showed orcein-positive granules in their cytoplasm (white arrows). 
In this case, such deposition was found in zone 1 hepatocytes around <1/3 of portal 
tracts in the liver biopsy specimen (score 1) (orcein stain, 1000× magnification). (G) 
Orcein-positive granules are deposited in most zone 1 hepatocytes around 1 portal 
tract. In this case, such deposition was found in zone 1 hepatocytes around >2/3 of 
portal tracts in the liver biopsy specimen (score 3) P, portal vein. (orcein stain, 400× 
magnification). Score 2 of deposition of orcein-positive granules represents the 
amount of deposition in zone 1 hepatocytes in 1/3 to 2/3 of portal tracts between (F) 
(score 1) and (G) (score 3). 
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Fig. 2 Distribution of each grade and score according to the new staging and grading system 
for PBC (A–E). (A) Cholangitis activity (CA). (B) Hepatitis activity (HA). (C) 
Fibrosis. (D) Bile duct loss. (E) Deposition of orcein-positive granules. Comparison of 
each stage for the new, Scheuer, and Ludwig systems (F–H). (G) and (H) show each 
population categorized by the new system in each stage according to the Scheuer and 
Ludwig systems, respectively. 
Fig. 3 Rates of development of cirrhosis-related conditions in each histological stage. (A) 
New staging system (B) Scheuer system. (C) Ludwig system. All p values were 
calculated using the log rank test.   
Fig. 4 Rates of development of cirrhosis-related conditions in each score of (A) fibrosis and 
(B and C) deposition of orcein-positive granules. (C) is the comparison with scores 
0–1 vs. scores 2–3 of deposition of orcein-positive granules. All p values were 
calculated using the log rank test.  
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Table 1. Scoring for the staging of primary biliary cirrhosis 
 
A. Fibrosis 
Score             Criterion 
0          No portal fibrosis or fibrosis limited to portal tracts 
1          Portal fibrosis with periportal fibrosis or incomplete septal fibrosis 
2          Bridging fibrosis with variable lobular disarray 
3          Liver cirrhosis with regenerative nodules and extensive fibrosis 
 
B. Bile duct loss 
Score             Criterion 
0          No bile duct loss 
1          Bile duct loss in <1/3 of portal tracts 
2          Bile duct loss in 1/3–2/3 of portal tracts 
3          Bile duct loss in >2/3 of portal tracts 
 
C. Deposition of orcein-positive granules (a 
Score            Criterion 
0          No deposition of granules 
1          Deposition of granules in a couple of zone 1 hepatocytes at <1/3 of portal tracts 
2          Deposition of granules in a variable number of zone 1 hepatocytes at 1/3–2/3 of portal tracts 
3          Deposition of granules in most zone 1 hepatocytes at >2/3 of portal tracts 
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Table 2. Grading of the necroinflammatory activity of primary biliary cirrhosis 
 
A. Cholangitis activity (CA) 
Grade                    Criteria 
0 (no activity)          No cholangitis but mild damage to the epithelium of the duct may be present 
1 (mild activity)        One evident chronic cholangitis in the specimen 
2 (moderate activity)    More than two bile ducts with evident chronic cholangitis 
3 (marked activity)      At least one CNSDC in the specimen 
 
B. Hepatitis activity (HA) 
Grade                   Criteria 
0 (no activity)           No interface hepatitis and no or minimum lobular hepatitis 
1 (mild activity)         Interface hepatitis affecting 10 continuous hepatocytes at a limiting plate in one portal tract or 
fibrous septa and mild-to-moderate lobular hepatitis 
2 (moderate activity)    Interface hepatitis affecting 10 continuous hepatocytes at a limiting plates in more than two 
portal tracts or fibrous septa and mild-to-moderate lobular hepatitis 
3 (marked activity)      Interface hepatitis affecting 20 continuous hepatocytes at limiting plate in more than half of the 
portal tracts and modetate lobular hepatitis or bridging/zonal necrosis 
 

















Y. Kakuda  et al. Table  
 
Table 3. Clinical characteristics of patients 
 Total (n = 152) (n = 110) (a 
Age (mean ± SD, years) 57 ± 12 56 ± 12 
Sex (males : females) 17:135 11:99 
Observation period  
(mean ± SD, years) 
5.6 ± 5.8 
 (range, 0–24.8 years) 
5.7 ± 6.0 
(range, 0–24.8 years) 
AMA or M2Ab (+:−) 117:35 (positivity 77.0%) 85:25 (positivity 77.2%) 
ANA (+:−) 94:57 (positivity 62.3%)(b 70:39 (positivity 64.2%) 
Symptomatic:asymptomatic 43:108 29:81 
UDCA treatment (cases) 136 96 
Bezafibrate addition (cases) 26 22 
Corticosteroids addition (cases) 19(c  14 
Laboratory data at the time of biopsy   
Alp (mean ± SD, IU/L) 592 ± 501 522 ± 374 
γ-GTP (mean ± SD, IU/L) 224 ± 203 221 ±207 
AST (mean ± SD, IU/L) 49.7 ± 31.5 47.6 ± 28.4 
ALT (mean ± SD, IU/L) 50.6 ± 38.6 50.7 ± 38.3 
Total bilirubin (mean ± SD, mg/dL) 0.89 ± 1.21 0.76 ± 0.43 
Albumin (mean ± SD, g/dL) 4.16 ± 0.56 (d 4.21 ± 0.48 
Prothrombin time (mean ± SD, sec) 11.4 ± 0.81 (d 11.6 ± 0.61 
IgG (mean ± SD, mg/dL) 1897 ± 611 1798 ± 536 
IgM (mean ± SD, mg/dL) 376 ± 267 370 ± 280 
(a Cases which had not been used in our previous study (6). (b ANA was available for 151 patients. (c 13 cases also had 
corticosteroids for other autoimmune disorders. (d Serum albumin concentration and prothrombin time were available for 
95 patients (at a single center, Kanazawa University Hospital). Abbreviations: SD, standard deviation; AMA, 






Y. Kakuda  et al. Table  
 
Table 4.  Analysis between grading and staging systems and laboratory data for primary biliary cirrhosis using 
Spearman's correlation coefficient by rank test (n = 110) 

















































































−0.0192 0.0119 0.0815 0.1626 0.2687* 0.2034* 0.2695* 0.0937 
p =  
0.8443 
p =  
0.9028 
p =  
0.4041 










IgM  0.1156 −0.0104 0.1226 0.1270 0.1590 0.1793 0.1949* 0.1909* 
p =  
0.2334 
p =  
0.9146 
p =  
0.2062 
p =  
0.1901 
p =  
0.1003 






IgG  −0.0241 0.2122* 0.0889 0.1868 0.0845 0.0782 0.0690 0.2105* 




p =  
0.3674 
p =  
0.0563 
p =  
0.3916 
p =  
0.4278 






−0.1887 0.0440 −0.0007 0.0259 0.1128 0.1371 0.0640 0.0854 
p =  
0.0685 
p =  
0.6734 
p =  
0.9944 
p =  
0.8040 
p =  
0.2790 
p =  
0.1877 





0.1738 0.1209 0.1272 −0.0204 −0.0422 −0.0231 0.0848 −0.0048 
p =  
0.0720 
p =  
0.2126 
p =  
0.1897 
p =  
0.8339 
p =  
0.6647 
p =  
0.8127 




Values with asterisks represent coefficients regarded as significantly correlated when p < 0.05 (lower lane). The value in 
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Table 5. Patients with cirrhosis-related conditions 
Case 
No. 
“Cirrhosis-related conditions” Development 




Varices  Ascites HE HCC Hyper- 
bilirubinemia 
1 + n.d. + n.d. n.d. + * 
2 + n.d. n.d. n.d. n.d. n.d. * 
3 n.d. n.d. n.d. n.d. + + * 
4 n.d. n.d. n.d. n.d. n.d. + * 
5 n.d. + n.d. n.d. n.d. n.d. * 
6 + n.d. + n.d. n.d. n.d. * 
7 n.d. n.d. + n.d. n.d. n.d.     * 
8 + n.d. n.d. n.d. n.d. n.d. * 
9 n.d. n.d. + n.d. n.d. + * 
10 n.d. + n.d. n.d. n.d. n.d. 3** 
11 n.d. + n.d. n.d. n.d. n.d. 11** 
12 n.d. + n.d. n.d. n.d. n.d. 21** 
13 n.d. n.d. + n.d. n.d. n.d. 48** 
14 n.d. + n.d. n.d. n.d. + 54** 
15 n.d. n.d. + n.d. n.d. n.d. 57** 
16 n.d. + n.d. n.d. n.d. n.d. 60** 
17 n.d. n.d. n.d. n.d. n.d. + 67** 
18 + n.d. n.d. n.d. n.d. n.d. 80** 
19 n.d. n.d. n.d. + n.d. n.d. 107** 
20 n.d. n.d. + n.d. n.d. + 122** 
21 n.d. n.d. + n.d. n.d. + 182** 
22 + n.d. n.d. n.d. n.d. n.d. 198** 
23 n.d. n.d. + n.d. n.d. n.d. 215** 
Abbreviations: HE, Hepatic encephalopathy; HCC, Hepatocellular carcinoma; +, present; n.d., not detected.  































Grade Grade Score 
Fig.2 
Score 
A B C D E 
(n) 
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H G 
0 1 2 3 
0 1 2 3 
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Stage Scheuer stage Ludwig stage 
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Fibrosis 
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